Real-world study on the application effect of national centralized acquisition with quantity of Moxifloxacin Hydrochloride Sodium Chloride Injection in the treatment of community acquired pneumonia
LIU Yan1 YU Jing2 LIU Huan3 ZHANG Yanjing2 ZHAO Mingyi1
1.School of Life Science and Biopharmaceutical, Shenyang Pharmaceutical University, Liaoning Province, Shenyang 110016, China;
2.Department of Clinical Pharmacy, the First Hospital of Hebei Medical University, Hebei Province, Shijiazhuang 050031, China;
3.Department of Pharmacy, the First Hospital of Hebei Medical University, Hebei Province, Shijiazhuang 050031, China
Abstract：Objective To compare the efficacy and safety of national centralized acquisition with quantity of Moxifloxacin Hydrochloride Sodium Chloride Injection and innovator drug in the treatment of community acquired pneumonia (CAP). Methods A total of 250 CAP patients admitted to the First Hospital of Hebei Medical University from October 2020 to October 2021 were retrospectively collected. Among them, 63 patients who used the national centralized acquisition with quantity of Moxifloxacin Hydrochloride Sodium Chloride Injection were included in the collection group, 187 patients who received innovator drug as the innovator drug group. The effectiveness and safety of the two groups were compared after using propensity score matching to adjust the differences between the two groups. Results After matching, 61 patients were included in the collection group and 111 patients in the innovator drug group. There was no significant difference in treatment effect between the two groups at 72 h of treatment and discharge (P＞0.05). At discharge, the body temperature, C-reactive protein, and procalcitonin in the two groups were lower than those at admission, the differences were statistically significant (P＜0.05). There were no significant differences in temperature, C-reactive protein, and procalcitonin between the two groups at discharge (P＞0.05). There was no significant difference in the total incidence of adverse reactions between the two groups (P＞0.05). Conclusion The efficacy and safety of national centralized acquisition with quantity of Moxifloxacin Hydrochloride Sodium Chloride Injection are comparable to the innovator drug in the treatment of CAP, and can be widely used in clinical practice.
刘琰1 于静2 刘欢3 张彦景2 赵明沂1. 国家集中带量采购盐酸莫西沙星氯化钠注射液治疗社区获得性肺炎应用效果的真实世界研究[J]. 中国医药导报, 2023, 20(26): 134-137.
LIU Yan1 YU Jing2 LIU Huan3 ZHANG Yanjing2 ZHAO Mingyi1. Real-world study on the application effect of national centralized acquisition with quantity of Moxifloxacin Hydrochloride Sodium Chloride Injection in the treatment of community acquired pneumonia. 中国医药导报, 2023, 20(26): 134-137.
京公网安备 11010502046598号